MNOV - MediciNova Inc

MNOV - MediciNova Inc

https://medicinova.com

Momentum: Bearish

Recent News

Powered by Alpha Vantage

MediciNova to Present at the H.C. Wainwright 27th Annual Global Investment Conference

GlobeNewswire • 1 week, 5 days ago • score: 0.07

LA JOLLA, Calif., Sept. 03, 2025 ( GLOBE NEWSWIRE ) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market ( NASDAQ:MNOV ) and the Standard Market of the Tokyo Stock Exchange ( Code Number: 4875 ) ( the "Company" ) , announces that Yuichi Iwaki, MD., Ph.D., President ...

MediciNova Achieves Enrollment in COMBAT-ALS Clinical Trial

GlobeNewswire • 2 weeks, 5 days ago • score: 0.11

LA JOLLA, Calif., Aug. 26, 2025 ( GLOBE NEWSWIRE ) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market ( NASDAQ: MNOV ) and the Standard Market of the Tokyo Stock Exchange ( Code Number: 4875 ) , announces that it successfully achieved enrollment of the target ...

MediciNova Announces Signing of a Standby Equity Purchase Agreement for up to $30 Million - MediciNova ( NASDAQ:MNOV )

Benzinga • 1 month, 2 weeks ago • score: 0.34

LA JOLLA, Calif., July 31, 2025 ( GLOBE NEWSWIRE ) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market MNOV and the Standard Market of the Tokyo Stock Exchange ( Code Number: 4875 ) ( the "Company" ) , announces a Standby Equity Purchase Agreement ( SEPA ) for up ...

First Patient Enrolled in NIH-Funded Expanded Access Program ( EAP ) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis ( ALS ) Patients

GlobeNewswire • 5 months ago • score: 0.08

LA JOLLA, Calif., April 08, 2025 ( GLOBE NEWSWIRE ) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market ( NASDAQ:MNOV ) and the Standard Market of the Tokyo Stock Exchange ( Code Number: 4875 ) , today announced enrollment of the first patient in the NIH-funded ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapies for the treatment of serious diseases with unmet medical needs in the United States. The company is headquartered in La Jolla, California.

52W High

$2.55

52W Low

$1.13

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.43

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-2.65

EV/Revenue (<3 favorable)

217.77

P/S (TTM) (<3 favorable)

470.06

P/B (<3 favorable)

1.35

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

2.98%

Institutions (25–75% balanced)

21.82%

Shares Outstanding

49,046,200

Float

42,081,200

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

134,600

Gross Profit (TTM)

18,250

EPS (TTM)

-0.25

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-26.80%

ROE (TTM) (>15% strong)

-0.23%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

-0.0221

Previous

-0.0170

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025